1. Home
  2. KRNY vs PHAT Comparison

KRNY vs PHAT Comparison

Compare KRNY & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRNY
  • PHAT
  • Stock Information
  • Founded
  • KRNY 1884
  • PHAT 2018
  • Country
  • KRNY United States
  • PHAT United States
  • Employees
  • KRNY 556
  • PHAT N/A
  • Industry
  • KRNY Savings Institutions
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • KRNY Finance
  • PHAT Health Care
  • Exchange
  • KRNY Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • KRNY 410.4M
  • PHAT 289.0M
  • IPO Year
  • KRNY 2005
  • PHAT 2019
  • Fundamental
  • Price
  • KRNY $6.34
  • PHAT $3.22
  • Analyst Decision
  • KRNY Buy
  • PHAT Strong Buy
  • Analyst Count
  • KRNY 2
  • PHAT 5
  • Target Price
  • KRNY $7.75
  • PHAT $17.80
  • AVG Volume (30 Days)
  • KRNY 328.5K
  • PHAT 1.7M
  • Earning Date
  • KRNY 04-24-2025
  • PHAT 05-01-2025
  • Dividend Yield
  • KRNY 6.91%
  • PHAT N/A
  • EPS Growth
  • KRNY N/A
  • PHAT N/A
  • EPS
  • KRNY N/A
  • PHAT N/A
  • Revenue
  • KRNY $148,766,000.00
  • PHAT $81,859,000.00
  • Revenue This Year
  • KRNY $17.60
  • PHAT $201.74
  • Revenue Next Year
  • KRNY $22.31
  • PHAT $114.16
  • P/E Ratio
  • KRNY N/A
  • PHAT N/A
  • Revenue Growth
  • KRNY 4.47
  • PHAT 3055.70
  • 52 Week Low
  • KRNY $5.31
  • PHAT $2.21
  • 52 Week High
  • KRNY $8.59
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • KRNY 53.94
  • PHAT 25.16
  • Support Level
  • KRNY $6.23
  • PHAT $4.06
  • Resistance Level
  • KRNY $6.43
  • PHAT $4.45
  • Average True Range (ATR)
  • KRNY 0.18
  • PHAT 0.34
  • MACD
  • KRNY 0.03
  • PHAT -0.15
  • Stochastic Oscillator
  • KRNY 72.58
  • PHAT 3.57

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. It is also heavily into secured and unsecured business and consumer loans. The bank's primary source of income is net interest income.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: